For the first time ever, an experimental drug is showing great promise in slowing the progression of Alzheimer's disease. Drug maker Eli Lilly says data from two large studies show memory decline in patients taking the drug slowed by more than a third over an 18-month period.
Dr. Maria Carrillo from the Alzheimer's Association says, "There's a lot of excitement about this result. It is the first time we are seeing a slowing of cognitive decline in patients with Alzheimer's disease in this type of drug treatment."
The drug, called Solanezumab, did not affect physical function in patients. But in the 2,000 people tested so far, many consider it a blessing that it helped slow memory decline. The drug works by blocking a protein that forms deposits in the brain. So far, the study suggests it is the newly diagnosed patients with mild patients who would benefit the most from the drug.
Copyright 2012 KCBD. All rights reserved.